These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33051308)

  • 41. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
    Eckel-Passow JE; Lachance DH; Molinaro AM; Walsh KM; Decker PA; Sicotte H; Pekmezci M; Rice T; Kosel ML; Smirnov IV; Sarkar G; Caron AA; Kollmeyer TM; Praska CE; Chada AR; Halder C; Hansen HM; McCoy LS; Bracci PM; Marshall R; Zheng S; Reis GF; Pico AR; O'Neill BP; Buckner JC; Giannini C; Huse JT; Perry A; Tihan T; Berger MS; Chang SM; Prados MD; Wiemels J; Wiencke JK; Wrensch MR; Jenkins RB
    N Engl J Med; 2015 Jun; 372(26):2499-508. PubMed ID: 26061753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
    Killela PJ; Pirozzi CJ; Healy P; Reitman ZJ; Lipp E; Rasheed BA; Yang R; Diplas BH; Wang Z; Greer PK; Zhu H; Wang CY; Carpenter AB; Friedman H; Friedman AH; Keir ST; He J; He Y; McLendon RE; Herndon JE; Yan H; Bigner DD
    Oncotarget; 2014 Mar; 5(6):1515-25. PubMed ID: 24722048
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas.
    Batool SM; Escobedo AK; Hsia T; Ekanayake E; Khanna SK; Gamblin AS; Zheng H; Skog J; Miller JJ; Stemmer-Rachamimov AO; Cahill DP; Balaj L; Carter BS
    Nat Commun; 2024 Aug; 15(1):7074. PubMed ID: 39152110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
    Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
    Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
    Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Sensitive Detection of Telomerase Reverse Transcriptase Promoter Mutation by Amplification Refractory Mutation System-PCR.
    Liu J; Zhao Z; Sun M; Chen K; Yuan W; Jiang G
    Genet Test Mol Biomarkers; 2016 Feb; 20(2):90-3. PubMed ID: 26741813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma.
    Trung NT; Hoan NX; Trung PQ; Binh MT; Van Tong H; Toan NL; Bang MH; Song LH
    Sci Rep; 2020 May; 10(1):8181. PubMed ID: 32424223
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
    Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN
    Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Telomerase reverse transcriptase promoter mutation- and O
    Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
    Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The Present and Future of Less-invasive Liquid Biopsy for the Diagnosis of Gliomas and Brain Tumors].
    Natsumeda M; On J; Watanabe J; Tsukamoto Y; Okada M; Fujii Y; Adachi J; Nishikawa R
    No Shinkei Geka; 2021 May; 49(3):527-534. PubMed ID: 34092558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.
    Iyer PC; Dadu R; Barque A; Zanelli C; Zheng X; Jiang H; Walsh PS; Hao Y; Huang J; Klopper JP; Kloos RT; Cabanillas M
    J Clin Endocrinol Metab; 2024 Aug; 109(9):2269-2273. PubMed ID: 38441247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High incidence of TERT mutation in brain tumor cell lines.
    Johanns TM; Fu Y; Kobayashi DK; Mei Y; Dunn IF; Mao DD; Kim AH; Dunn GP
    Brain Tumor Pathol; 2016 Jul; 33(3):222-7. PubMed ID: 26960334
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines.
    Bai H; Bai S; Li X; Zhang Y; Li Y; He F; Cheng W
    Biomed Res Int; 2021; 2021():3271395. PubMed ID: 34159191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulatory Single Nucleotide Polymorphism Increases TERT Promoter Activity in Thyroid Carcinoma Cells.
    Hirokawa T; Arimasu Y; Chiba T; Nakazato Y; Fujiwara M; Kamma H
    Pathobiology; 2020; 87(6):338-344. PubMed ID: 33227798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TERT Immunohistochemistry as a Surrogate Marker for TERT Promoter Mutations in Infiltrating Gliomas.
    Dono A; Moosvi AM; Goli PS; Bellman AC; Aung PP; Esquenazi Y; Ballester LY
    Appl Immunohistochem Mol Morphol; 2023 May-Jun 01; 31(5):288-294. PubMed ID: 36952585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Telomerase Reverse Transcriptase Promoter Mutations in A Cohort Of Adult Gliomas - Clinicopathological Correlates.
    Balakumar S; Pai R; Chacko AG; Patel B; Nancy R; Balakrishnan R; Sarkar S; Sampath G; Chacko G
    Neurol India; 2022; 70(3):953-959. PubMed ID: 35864624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.
    Panditharatna E; Kilburn LB; Aboian MS; Kambhampati M; Gordish-Dressman H; Magge SN; Gupta N; Myseros JS; Hwang EI; Kline C; Crawford JR; Warren KE; Cha S; Liang WS; Berens ME; Packer RJ; Resnick AC; Prados M; Mueller S; Nazarian J
    Clin Cancer Res; 2018 Dec; 24(23):5850-5859. PubMed ID: 30322880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.